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Abstract
Background: To determine the cost-effectiveness of the percutaneous mitral valve repair (PMVR) using Carillon®
Mitral Contour System® (Cardiac Dimensions Inc., Kirkland, WA, USA) in patients with congestive heart failure
accompanied by moderate to severe functional mitral regurgitation (FMR) compared to the prolongation of
optimal medical treatment (OMT).
Methods: Cost-utility analysis using a combination of a decision tree and Markov process was performed. The
clinical effectiveness was determined based on the results of the Transcatheter Implantation of Carillon Mitral
Annuloplasty Device (TITAN) trial. The mean age of the target population was 62 years, 77 % of the patients were
males, 64 % of the patients had severe FMR and all patients had New York Heart Association functional class III.
The epidemiological, cost and utility data were derived from the literature. The analysis was performed from the
German statutory health insurance perspective over 10-year time horizon.
Results: Over 10 years, the total cost was €36,785 in the PMVR arm and €18,944 in the OMT arm. However,
PMVR provided additional benefits to patients with an 1.15 incremental quality-adjusted life years (QALY) and
an 1.41 incremental life years. The percutaneous procedure was cost-effective in comparison to OMT with an
incremental cost-effectiveness ratio of €15,533/QALY. Results were robust in the deterministic sensitivity analysis. In the
probabilistic sensitivity analysis with a willingness-to-pay threshold of €35,000/QALY, PMVR had a 84 % probability of being
cost-effective.
Conclusions: Percutaneous mitral valve repair may be cost-effective in inoperable patients with FMR due to heart failure.
Keywords: Heart failure, Functional mitral regurgitation, Percutaneous valve repair treatment, Cost-utility analysis,
Germany
Background
Functional mitral regurgitation (FMR) is a common con-
dition that can occur secondary to systolic heart failure
and dilated left ventricular cardiomyopathy [1–4]. The
cornerstone of clinical management is medical therapy
with surgical valve replacement or repair, which is not
possible in severely diseased patients with contraindications
to surgery and general anesthesia [5, 6]. Although FMR can
lead to increased mortality, reduced functional capacity and
increased healthcare cost, only a few targeted treatments,
addressing FMR, are available. There is ongoing debate
about the optimal intervention for FMR, its timing and ef-
fectiveness [7–11].
The Carillon® Mitral Contour System® (Cardiac Dimen-
sions Inc., Kirkland, WA, USA) is a novel percutaneous
coronary sinus-based mitral annuloplasty device designed
to treat FMR. This approach has been shown to signifi-
cantly reduce FMR, improve functional capacity and quality
of life as well as induce reverse left ventricular remodeling
[12–14]. Given these findings and the high prevalence of
patients with heart failure and FMR, it is important to
understand the economic implications of percutaneous
mitral valve repair (PMVR). After safety, efficacy and
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effectiveness aspects, cost-effectiveness is becoming the
fourth hurdle for reimbursement of novel technologies
in most developed countries [15–17]. The current clinical
evidence for CE-marked Carillon® Mitral Contour System®
is based on the single arm AMADEUS [12] and the
non-randomized controlled Transcatheter Implantation
of Carillon Mitral Annuloplasty Device (TITAN) [13]
trials, which makes it possible to perform an early eco-
nomic evaluation to inform decision-making about the
cost-effectiveness of PMVR and ensure the timely ac-
cess of patients to this treatment option.
The objective of the study was to determine, in German
settings, the cost-effectiveness of PMVR using the Carillon®
Mitral Contour System® in patients with congestive heart
failure and moderate to severe FMR with normal QRS




The combination of a decision tree and a Markov
process [18–20] was used to assess the economic value
of percutaneous annuloplasty in patients with FMR. The
cycle length was one month. The model starts with a de-
cision tree (Fig. 1), in which the patients undergoing
PMVR may have several possible outcomes, including
discharge from the hospital without complications, peri-
operative complications with subsequent discharge from
the hospital, unsuccessful device implantation with sub-
sequent removal of the device during the initial proced-
ure or death. All serious complications related to the
implantation procedure were selected from the pub-
lished TITAN trial [13]. During the first month of the
model, the patients in the optimal medical treatment
arm could die or stay alive. Decision tree estimates the
cost-effectiveness for the first month in the model.
Thereafter, all patients in both arms entered the Markov
model.
The structure of the follow-up Markov model was ap-
plied to both treatment arms. The Markov model con-
sists of four health states representing the four New
York Heart Association (NYHA) functional classes. Pa-
tients may progress from one NYHA class to another. In
each state, hospitalization and death are possible. The
probability of hospitalization and death is higher with in-
creasing NYHA classes. Each state of the Markov model
has associated cost and utility based on the status of
health-related quality of life.
The basis for the analysis is that PMVR, by improving
symptoms (i.e., improving the patient’s NYHA functional
class) through the reduction of FMR, will reduce both
mortality and hospitalizations compared with the pro-
longation of optimal medical treatment.
Clinical inputs
Search for relevant clinical, cost and utility inputs was
performed in the Medline database using key words
“functional mitral regurgitation”, “prognosis”, “mortal-
ity”, “cost”, “NYHA class” in April 2012 and repeated in
August 2014.
Monthly transition probabilities across NYHA classes for
the Carillon and optimal medical therapy arms (Table 1)
were derived from the TITAN trial [13]. The TITAN trial
enrolled fifty-three patients with dilated ischemic or
non-ischemic cardiomyopathy from seven European
centers. The inclusion criteria were 1) at least moder-
ate (2+) FMR, 2) a left ventricular ejection fraction
(LVEF) <40 %, 3) NYHA class II-IV, 4) a 6 min walk
Fig. 1 Decision tree and Markov model structure. NYHA, New York Heart Association; OMT, optimal medical treatment; PMVR, percutaneous
mitral valve repair
Borisenko et al. BMC Cardiovascular Disorders  (2015) 15:43 Page 2 of 11
distance between 150 and 450 m and 5) a stable heart
failure medication regimen. Thirty-six patients underwent
permanent device implantation and seventeen patients had
the device recaptured intra-operatively (i.e., device was
removed) either for clinical indications (i.e., transient
coronary compromise) or for a protocol defined indica-
tion (i.e., <1 grade FMR reduction). Both groups under-
went serial follow-ups with the non-implanted cohort
serving as a non-randomized, non-blinded comparator
group. Data for 17 patients with device recaptured after
unsuccessful implantation have been used to obtain
transition probabilities in the optimal medical manage-
ment (control) arm in the model. Compared with the
control group, clinically and statistically significant reduc-
tion in FMR (regurgitant volume, effective regurgitant
orifice area (EROA), vena contracta, mitral regurgitation jet
area/left atrial area) was demonstrated. Different transition
probabilities were applied for the first month, for months 2
to 11, and from month 12 and onwards. As the TITAN trial
provided limited data about the transitions from NYHA
class IV to other classes, an assumption was made about
these transitions being similar to transitions from NYHA
class III. It was assumed that NYHA class I does not lead
to increased mortality. Clinical inputs are presented in
Table 2.
The probability of hospitalization due to worsening of
heart failure was derived from the literature [21]. Age-
and gender-specific general mortality was derived from
German life tables [6]. Excessive all-cause mortality in
relation with the NYHA class was also derived from the
literature [22].
Functional mitral regurgitation is an independent pre-
dictor of mortality and hospitalization in patients with
chronic heart failure [23–25]. In the model, the add-
itional risk of mortality and hospitalization in patients
with severe FMR versus patients with mild/moderate
FMR or no FMR was introduced. Functional mitral
regurgitation was classified as mild/moderate with an ef-
fective regurgitant orifice area (EROA) ≤0.2 cm2 and as
severe with an EROA ≥0.2 cm2.
Patients in the PMVR arm experienced a decrease in
FMR and an improvement in NYHA class starting the
1st month after the treatment. The long-term follow-up
of these patients (3 years) has demonstrated a stable and
durable effect of PMVR over time and, therefore, a sus-
tained FMR reduction was assumed. According to the
results of the TITAN trial, the patients in the control
group had no improvement in FMR.
An intention-to-treat approach was used to simulate
disease progression in the patients with unsuccessful de-
vice placement. In this sub-group, the degree of FMR
and the NYHA functional classes were similar to the op-
timal medical treatment arm.
Resource utilization and cost data
All resource use and cost data were derived from German
sources (Table 2). The cost of PMVR was calculated from
relevant German diagnosis-related group (DRG) (F19C)
with the subtracted cost of implant and the added cost of
the Carillon device. Peri-operative myocardial infarction
was reported among the 20 most prevalent secondary diag-
noses for the DRG, and it was assumed that no additional
cost was incurred to manage this event. Based on clinical
opinions, 14 additional days of hospital stay would be
needed to treat a coronary sinus perforation. The basic
DRG tariff covers the treatment for 2 to 10 days of hospital
stay (average of 5.2 days). Therefore, incremental costs were
applied only for the extra days of hospital stay necessary to
treat a vessel perforation. The cost of the device and
Table 1 Transition probabilities between NYHA functional
classes [13]
Transition probabilities in cycle 1
NYHA I NYHA II NYHA III NYHA IV
Optimal medical treatment arm
NYHA Class III 0.00 0.17 0.75 0.08
PMVR arm
NYHA Class III 0.10 0.73 0.13 0.03
Transition probabilities in cycles 2–11
NYHA I NYHA II NYHA III NYHA IV
Optimal medical treatment arm
NYHA Class I 0.00 0.00 0.00 0.00
NYHA Class II 0.00 0.67 0.00 0.33
NYHA Class III 0.00 0.17 0.83 0.00
NYHA Class IV 0.00 0.00 0.17 0.83
PMVR arm
NYHA Class I 0.25 0.75 0.00 0.00
NYHA Class II 0.11 0.63 0.26 0.00
NYHA Class III 0.00 0.50 0.50 0.00
NYHA Class IV 0.00 0.00 0.50 0.50
Transition probabilities in cycle 12 and onwards
NYHA I NYHA II NYHA III NYHA IV
Optimal medical treatment arm
NYHA Class I 0.00 0.00 0.00 0.00
NYHA Class II 0.00 0.50 0.50 0.00
NYHA Class III 0.00 0.67 0.33 0.00
NYHA Class IV 0.00 0.00 0.67 0.33
PMVR arm
NYHA Class I 0.67 0.33 0.00 0.00
NYHA Class II 0.12 0.71 0.18 0.00
NYHA Class III 0.00 0.40 0.60 0.00
NYHA Class IV 0.00 0.00 0.40 0.60
NYHA, New York Heart Association; PMVR, percutaneous mitral valve repair
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Table 2 Clinical, cost and utility inputs
Variable Base Case
Value
Range Distribution for probabilistic
sensitivity analysis
Reference
Characteristics of patients’ population
Age, years 62 50–80 Normal [13]
(SD =12)
Male gender, % 77 0–100 Beta
Proportion of patients with severe MR
at baseline in both arms
0.639 0.511–0.766 Beta
(α = 23; β = 13)
Proportion of patients with severe MR
between 1 and 5 months in PMVR arm
0.35 0.28–0.42 Beta
(α = 12; β = 22)
Proportion of patients with severe MR
from 6 months and onwards in PMVR arm
0.258 0.206–0.309 Beta
(α = 8; β = 23)
Effectiveness data and transition probabilities
Probability of peri-procedural mortality 0.019 0.01–0.03 Beta [13]
(α = 1; β = 52)
Probability of myocardial infarction, which
leads to PCI
0.04 0.02–0.06 Beta
(α = 2; β = 51)
Probability of vessel perforation 0.02 0–0.03 Beta
(α = 1; β = 52)
Probability of unsuccessful percutaneous
annuloplasty
0.32 0.05–0.40 Beta
(α = 17; β = 36)
Probability of arrhythmia 0.04 0.02–0.06 Beta Assumption
(α = 2; β = 51)
Six-month probability of excess mortality for
NYHA class II
0.04 0.02–0.06 Beta [22]
(α = 4; β = 96)
Six-month probability of excess mortality for
NYHA class III
0.07 0.035–0.105 Beta
(α = 7; β = 93)
Six-month probability of excess mortality for
NYHA class IV
0.28 0.14–0.42 Beta
(α = 28; β = 72)
Monthly probability of hospitalization for
NYHA class I
0.015 0.008–0.023 Beta [21]
(α = 1.5; β = 98.5)
Monthly probability of hospitalization for
NYHA class II
0.024 0.012–0.036 Beta
(α = 2.4; β = 97.6)
Monthly probability of hospitalization for
NYHA class III
0.024 0.012–0.036 Beta
(α = 2.4; β = 97.6)
Monthly probability of hospitalization for
NYHA class IV
0.154 0.077–0.231 Beta
(α = 15.4; β = 84.6)
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Table 2 Clinical, cost and utility inputs (Continued)
Relative risk for all-cause mortality with
present severe MR
1.5 1.1–1.9 Log-normal (SElog = 0.26) [23]
Relative risk for hospitalization due to
HF with present severe MR
1.7 1.3–2.1 Log-normal (SElog = 0.33)
Resource utilization and cost data
Cost of Carillon device, € 18,000 12,600–23,400 - Cardiac Dimensions, Inc.
Cost of PMVR placement procedure, € 4844 3391–6297 - G-DRG code F19C
Cost of treatment of vessel perforation
after PMVR placement, €
1998 1399–2597 -
Percentage of patients being hospitalized
with stay in intensive care unit
7.2 % - Dirichlet [27]
Percentage of patients being hospitalized
with stay in coronary care unit
25.6 % -
Percentage of patients being hospitalized
with CABG performed
0.3 % -
Percentage of patients being hospitalized
with PTCA performed
0.2 % -
Percentage of patients being hospitalized
with heart transplantation performed
2.6 % -
Percentage of patients being hospitalized
with no procedure performed
62.3 % -
Cost of hospitalization with stay in intensive
care unit, €
5004 3503–6506 - G-DRG code F62A 2013
Cost of hospitalization with stay in coronary
care unit, €
5004 3503–6506 - G-DRG code F62A 2013
Cost of hospitalization with CABG
performed, €
15,056 10,539–19,573 - G-DRG code F06E
Cost of hospitalization with PTCA
performed, €
3793 2655–4931 - G-DRG code F56B plus ZE101
Cost of hospitalization with heart
transplantation performed, €
86,337 60,436–112,239 - G-DRG code A05B 2013
Cost of hospitalization with no procedure
performed, €
2740 1918–3562 - G-DRG code F62B 2013
Annual cost of routine management of heart
failure in NYHA class I, €
495 258–1031 Gamma [26]
(α = 1;λ = 516)
Annual cost of routine management of heart
failure in NYHA class II, €
874 455–1821 Gamma
(α = 1;λ = 910)
Annual cost of routine management of heart
failure in NYHA class III, €
864 450–1800 Gamma
(α = 1;λ = 900)
Annual cost of routine management of heart
failure in NYHA class IV, €
929 484–1935 Gamma
(α = 1;λ = 967)
Utility data
Utility for NYHA I class 0.815 0.652–0.978 Beta [27]
(α = 395; β = 90)
Utility for NYHA II class 0.720 0.576–0.864 Beta
(α = 662; β = 257)
Utility for NYHA III class 0.590 0.472–0.708 Beta
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procedure for the cases of unsuccessful implantation was
included in the analysis and was assumed to be covered by
the statutory health insurance.
The cost of routine management of heart failure (in-
cluding the costs of physician, medication and rehabilita-
tion) according to the NYHA class was derived from a
recent analysis from the German Competence Network
Heart Failure [26]. The costs of hospitalization in the in-
tensive care unit and coronary care unit and the costs of
coronary artery bypass grafting, percutaneous translumi-
nal coronary angioplasty, heart transplantation and no
invasive procedures were derived from relevant German
DRGs. The proportion of hospitalized patients undergo-
ing invasive treatment and the type of invasive treatment
were extrapolated from the CARE-HF trial [27].
Only the direct costs were included and were pre-
sented in 2013 Euros. The inflation adjustment was per-
formed using the German consumer price index [28].
Utility data
Utility scores were assigned for each NYHA class irrespect-
ive of the treatment received and the hospitalization status.
Utility values were derived from the CARE-HF trial [27]. A
one-month utility decrement was applied to the Carillon
implantation procedure which assumes a similar reduction
in the quality of life after percutaneous coronary interven-
tion (0.043) [29].
Base-case analysis
The analysis was performed from the perspective of the
German statutory health insurance over a 10-year time
horizon.
The characteristics of the modeled cohort were pri-
marily derived from the TITAN trial: the mean age was
62 years (SD 12 years), 77 % were males, all patients had
a NYHA class III (as average NYHA class was 3.0 ± 0.24
in the TITAN trial) and 63 % had severe (MR 4+) FMR.
The incremental cost-effectiveness ratio (ICER) was
calculated by comparing the difference in the average
total costs and the difference in the average quality-
adjusted life years (QALY) among the model’s arms. The
intervention was considered cost-effective if the ICER
was below the willingness-to-pay threshold of €35,000/
QALY [30, 31]. All costs and outcomes beyond the first
year were discounted by 3.0 % annually following the
recommendations of the German Institute for Quality
and Efficiency in Health Care (IQWIG) [32]. The model
was constructed in Microsoft Excel 2010 (Microsoft
Corp., Redmond, Washington, USA).
Model validation
After confirming the validity of the results, a number
of “stress tests” were performed to evaluate the tech-
nical performance of the model. Subsequently, the re-
sults of the analysis (all-cause mortality at different
follow-ups) were compared with data from the TITAN
trial as well as two epidemiological studies of patients
with FMR [23, 25].
Sensitivity analysis
A one-way sensitivity analysis was performed to assess
the impact of varying the model parameters while hold-
ing other variables fixed at base-case values. The major
cost drivers were identified and the results of the sensi-
tivity analysis results were presented by means of a
Tornado diagram. In addition, analysis of fade-out ef-
fect for PMVR was performed with transition probabilities
between NYHA classes in PMVR arm being equal to OMT
arm after 3 years from the start of analysis (as maximum
length of observation in Carillon studies is 3 years [33]). In
addition to the base-case analysis over 10-year time hori-
zon, cost-effectiveness of PMVR was also estimated over a
lifetime horizon.
A probabilistic sensitivity analysis was also performed
with 5000 Monte Carlo simulations. A beta distribution
was used for the probabilities and utility values, a dirich-
let distribution was used for the probabilities of transi-
tion between NYHA classes and proportions of patients
receiving different treatments during hospitalization, and
a log-normal distribution was used for the relative risk.
DRG tariffs and cost of PMVR were not tested in prob-
abilistic sensitivity analysis, as there was no uncertainty
associated with them.
Ethics statement
Approval by ethics committee was not required, as study
did not involve human material or human data.
Table 2 Clinical, cost and utility inputs (Continued)
(α = 360; β = 250)
Utility for NYHA IV class 0.508 0.406–0.609 Beta (α = 52; β = 50)
Decrement for percutaneous
annuloplasty procedure
0.043 0.034–0.051 Beta [29]
(α = 96; β = 2129)
SD, standard deviation; MR, mitral regurgitation; PMVR, percutaneous mitral valve repair; NYHA, New York Heart Association
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Results
Model validation
Validation of the model showed that the model could
precisely predict all-cause mortality at one, two and five
years of follow-up (Fig. 2).
Base-case analysis
Over 10 years, the total cost in the PMVR arm was
€36,785 and €18,944 in the optimal medical treatment
arm (Table 3). Percutaneous mitral valve repair, however,
provided a significant benefit to the patients compared
with the optimal medical treatment (1.15 incremental
QALYs and 1.41 incremental life years). Cumulative
mortality was 13.8 % and 23.5 % at 1 year, 20.0 % and
33.0 % at 2 years, 35.6 % and 54.3 % at 5 years, and
55.5 % and 76.5 % at 10 years in the PMVR and optimal
medical treatment arms respectively.
The percutaneous mitral valve repair treatment was
cost-effective in comparison to optimal medical treat-
ment with an ICER of €15,533/QALY.
Sensitivity analysis
The results of the one-way sensitivity analysis were stable
with no single variable altering the cost-effectiveness of
PMVR (Fig. 3). The most sensitive variables were the cost
of the Carillon device, the age of the patient, the probability
of unsuccessful annuloplasty and the presence of severe
FMR at baseline.
In the analysis over lifetime horizon PMVR led to in-
cremental cost of €19,539, incremental life-years gained
of 3.23 and QALYs gained of 2.47. PMVR was more
cost-effective over lifetime (ICER of €7,914/QALY) com-
pared with base-case analysis over 10-year time horizon.
Analysis of fade-out effect for effectiveness of PMVR
showed that technology remains cost-effective with ICER
of €23,582/QALY. In this analysis, PMVR led to an in-
cremental cost of €20,662 (cost of €39,702 and €19,040
in the PMVR and optimal medical management arms re-
spectively), an incremental life years gained of 1.04 (life
years gained of 5.49 and 4.46 in the PMVR and optimal
medical management arms respectively) and an incre-
mental QALYs gained of 0.88 (QALYs gained of 3.78 and
2.90 in the PMVR and optimal medical management
arms respectively).
In the probabilistic sensitivity analysis with 5000 simula-
tions, PMVR led to an incremental cost of €14,868, an in-
cremental life-years gained of 0.81 and a QALYs gained of
0.77 (Fig. 4). Percutaneous mitral valve repair was cost-
effective compared with optimal medical treatment with an
ICER of €19,414/QALY. At a willingness-to-pay threshold
of €35,000/QALY, PMVR had a 84 % probability of being
cost-effective (Fig. 5). At a threshold of €50,000/QALY,
PMVR had a 93 % probability of being cost-effective.
Discussion
Patients with left ventricular dysfunction and FMR have
a poor prognosis [2, 3, 24, 25, 34]. In severely ill patients,
the number of treatment options is limited. A survey of
European patients with heart failure and mitral regurgi-
tation revealed that the determinants of preclusion of
surgical treatment include impaired LVEF, older age and
comorbidities [35], which are typical for heart failure pa-
tients with FMR.
Furthermore, patients with FMR have a normal mitral
apparatus because the pathophysiological mechanism
leading to mitral regurgitation is left ventricular dilata-
tion with the subsequent mal-coaptation of the mitral
leaflets. This has resulted in the ongoing evaluation of
an array of non-surgical methods to attempt to correct
mal-coaptation [5, 36].
Fig. 2 Results of the model validation. Scares represents the mean value from the validation study, triangles represent the mean value from the
model, and lines represent the 95 % credible interval for the modeled results
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Our study showed that PMVR using Carillon® Mitral
Contour System® leads to an incremental cost (€17,841),
but it also leads to significant additional clinical benefit
to patients with increments of QALY and life-years of
1.15 and 1.41, respectively. Overall, PMVR can be cost-
effective in German settings with an ICER of €15,533/
QALY.
The model utilized a Markov process on the basis of four
NYHA functional classes with each class sub-divided into
hospitalized and non-hospitalized states. Many published
decision analytic models in the field of heart failure have
utilized NYHA classes to trace the progression of symp-
toms [22, 27, 37–39]. Hospitalizations are also a common
determinant in economic evaluations, as they are one of
the main cost drivers of heart failure. Studies have shown
that hospitalizations account for 60–74 % of the total ex-
penditures of heart failure in France, the UK, The
Netherlands, New Zealand and Sweden [40–42]. A recent
analysis from Germany reports that the annual cost of heart
failure in Germany totals €2.8 billion of which €1.7 billion
is spent on in-patient facilities [43].
Results of the study are similar to published economic
evaluations of another percutaneous treatment for mitral
regurgitation, the MitraClip (Abbott Vascular, Santa Clara,
California) [44, 45]. The analyses, based on the Endovascu-
lar Valve Edge-to-Edge REpair High Risk Study [46], were
performed in the UK [44] and Canadian [45] settings and
both compared the MitraClip to optimized medical treat-
ment. In the UK study, over 10-year time horizon, the
MitraClip lead to an incremental QALYs of 2.04 and a
resulting ICER of £14,800/QALY. The Canadian study
employed a lifetime horizon for its base-case analysis and
reported an incremental QALYs of 1.73 and a resulting
ICER of $23,433/QALY. At a 10-year time horizon, the
MitraClip was also cost-effective with an ICER of $25,752/
QALY. In our study, a similar level of clinical benefits (in-
cremental QALYs of 1.15) and cost-effectiveness (ICER of
€15,533/QALY) were demonstrated.
Table 3 Results of the cost-utility analysis
Treatment arm Cost, € Incremental cost, € LYG Incremental LYG QALY gained Incremental QALY gained ICER, €/QALY
Optimal medical treatment 18,944 4.46 2.91
Percutaneous mitral valve repair 36,785 17,841 5.87 1.41 4.06 1.15 15,533
ICER – incremental cost-effectiveness ratio; LYG – life years gained; QALY – quality-adjusted life years
Fig. 3 Tornado diagram. The Tornado diagram shows the results of the sensitivity analyses on the cost-effectiveness of PMVR compared with optimal
medical treatment. The blue lines with a diagonal pattern reflect results while using maximum values in the sensitivity analysis and the orange
lines reflect results while using minimum values. The vertical line indicates the base-case incremental cost-effectiveness ratio. PMVR, percutaneous mitral
valve repair; QALY, quality-adjusted life year
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Our study has several limitations. First, the transition
probabilities between the different NYHA functional clas-
ses were based on a limited sample from the TITAN trial.
Due to the limited sample size, not all transitions were
possible in the base-case analysis. This limitation was ad-
dressed in the probabilistic sensitivity analysis. Second, the
model utilized clinical and surrogate (mitral regurgitation)
outcomes to predict mortality and hospitalization. Ideally,
data on the impact of PMVR on mortality and hospitaliza-
tions as well as the utility data should be obtained directly
from prospective randomized controlled trials rather than
extrapolated from multiple sources. Evidence in the field
of FMR is increasing and a more precise assessment may
be possible in the future. A third limitation relates to the
nature of the comparative effectiveness data for PMVR.
Data about change of level of mitral regurgitation were ob-
tained from the TITAN trial [13], in which the control
group consisted of patients who underwent unsuccessful
device placement, with explant of Carillon occurring dur-
ing the procedure. Ideally, the effectiveness data should be
obtained from a randomized controlled trial with an
intention-to-treat analysis to allow the assessment of out-
comes despite the real treatment received in groups with
balanced observed and unobserved baseline characteris-
tics. Nevertheless, in TITAN trial both groups had similar
baseline demographic and clinical characteristics. How-
ever, due to the absence of random allocation into the
treatment groups, there might be unobserved differences
between groups, which may impact the reported effective-
ness of PMVR. The TITAN trial had a sufficient follow-up
period and the differences in the studied FMR measures at
1, 6 and 12 months between groups are not likely ex-
plained by reasons other than the impact of the implanted
device. Finally, the maximum length of observation in
Carillon studies is 3 years [28] while the clinical effective-
ness was extrapolated over a 10-year time horizon in our
Fig. 4 Cost-effectiveness acceptability plane. QALY, quality-adjusted life year
Fig. 5 Cost-effectiveness acceptability curve. QALY, quality-adjusted life year
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model. Nevertheless, analysis of fade-out effect for PMVR
with effectiveness limited to 3 years showed that technol-
ogy remains cost-effective in comparison with optimal
medical treatment (ICER of €23,582/QALY). The afore-
mentioned limitations should be taken into consideration
when results of the present model are used to inform clin-
ical or payer decision-makers.
Conclusions
When compared with optimal medical treatment, PMVR
using the Carillon® Mitral Contour System® may be cost-
effective in inoperable patients with congestive heart fail-
ure who have moderate to severe FMR.
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